Inhibitors
Cat.No. | Name | Information |
---|---|---|
M1988 | Dabrafenib | Dabrafenib (free base) (GSK2118436A) is a V600 mutant BRAF-specific inhibitor. |
M3026 | Sorafenib | Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. |
M1774 | PLX-4720 | PLX-4720 is a selective BRAFV600E inhibitor with the IC50 values of 160 nM and 130 nM for B-Raf and BRK respectively. |
M1761 | Vemurafenib | Vemurafenib (PLX4032; RG7204; RO5185426) is the first and effective selective inhibitor of B-Raf, which can inhibit RAFV600E and C-RAF-1 activity with IC50 of 31 nM and 48 nM, respectively. Vemurafenib induces autophagy. |
M2319 | AZ628 | AZ628 is a potent inhibitor for wild-type CRAF and BRAF V600E with IC50 of 29 nM and 34 nM, respectively. |
M10880 | Rineterkib hydrochloride | Rineterkib hydrochloride (compound B) is an orally active inhibitor of RAF and ERK1/2 that exerts an antiproliferative effect by activating mutations in the MAPK pathway. This activity is particularly associated with KRAS-mutant non-small cell lung cancer, BRAF-mutant non-small cell lung cancer, KRAS-mutant pancreatic cancer, KRAS-mutant colon cancer, and KRAS mutant ovarian cancer. |
M10733 | Rineterkib | Rineterkib (compound B) is an orally active inhibitor of RAF and ERK1/2 that exerts an antiproliferative effect by activating mutations in the MAPK pathway. This activity is particularly associated with KRAS-mutant non-small cell lung cancer, BRAF-mutant non-small cell lung cancer, KRAS-mutant pancreatic cancer, KRAS-mutant colon cancer, and KRAS-mutant ovarian cancer. |
M10591 | AZ304 | AZ304 is a potent dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF with IC50 values of 79 nM and 38 nM respectively. |
M10475 | Lifirafenib (BGB-283) | Lifirafenib (BGB-283) is a novel potent and selective RAF Kinase and EGFR inhibitor with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant. |
M10438 | BI 882370 | BI 882370 is a highly potent and selective RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase. |
M10152 | Naporafenib | Naporafenib (also known as LXH254) is an orally available inhibitor of C-Raf and B-Raf with potential antineoplastic activity. |
M9492 | B-Raf inhibitor 1 | B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 µM and 2 nM for A375 proliferation and A375 p-ERK, respectively. |
M9008 | PLX7904 | PLX7904, also known as PB04, is a potent and selective paradox-breaker RAF inhibitor. |
M9007 | PLX8394 | PLX8394 is an orally bioavailable, potent and selective Raf inhibitor with IC50 of 5 nM. |
M8897 | B-Raf-IN-1 | B-Raf-IN-1 (MDK36057) is a potent b-Raf inhibitor with IC50 of 24 nM. |
M8886 | RAF709 | RAF709 is a novel Raf kinase inhibitor with IC50 values of 0.4 and 1.5 nM for c-Raf and b-Raf, respectively. |
M5327 | L-779450 | L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively. |
M3026 | Sorafenib | Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. |
M2927 | PF-04880594 | PF-04880594 is a RAF inhibitor for BRAF/BRAFV599E and c-RAF with IC50 of 0.19 nM/0.13 nM and 0.39 nM, >100-fold selectivity over CSNK1, JNK2/3 and p38. |
M2813 | LGX818 | LGX818 is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM. |
M2745 | GW5074 | GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted. |
M2319 | AZ628 | AZ628 is a potent inhibitor for wild-type CRAF and BRAF V600E with IC50 of 29 nM and 34 nM, respectively. |
M2235 | TAK-632 | TAK-632 is a potent and selective pan-RAF inhibitor. |
M2090 | MLN2480 | MLN2480 (BIIB-024) is an oral, selective pan-Raf kinase inhibitor. |
M2045 | CEP-32496 | CEP-32496 is a potent orally active BRAF inhibitor with IC50 of 14 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.